| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 19 |
| 1 | NIVOLUMAB | 15 |
| 2 | IPILIMUMAB | 13 |
| 3 | PEMETREXED | 13 |
| 4 | PEMETREXED DISODIUM | 13 |
| 5 | CISPLATIN | 11 |
| 6 | DEXAMETHASONE | 11 |
| 7 | DEXAMETHASONE 1.5 MG | 11 |
| 8 | CARBOPLATIN | 6 |
| 9 | LORLATINIB | 6 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | LOMUSTINE | 3 | 0.0012 |
| 1 | BRIGATINIB | 4 | 0.0011 |
| 2 | POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL | 1 | 0.0009 |
| 3 | LORLATINIB | 6 | 0.0008 |
| 4 | SELUMETINIB | 1 | 0.0006 |
| 5 | CICLOPIROX | 1 | 0.0004 |
| 6 | GLYCERIN SUPPOSITORY | 1 | 0.0004 |
| 7 | GLYCERIN SUPPOSITORIES | 1 | 0.0004 |
| 8 | PEMETREXED DISODIUM | 13 | 0.0003 |
| 9 | IPILIMUMAB | 13 | 0.0003 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CTLA-4-directed Blocking Antibody [EPC] | 13 | 0.0003 |
| 1 | Osmotic Diuretic [EPC] | 1 | 0.0002 |
| 2 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 1 | 0.0002 |
| 3 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 15 | 0.0002 |
| 4 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 20 | 0.0001 |
| 5 | Platinum-based Drug [EPC] | 17 | 0.0001 |
| 6 | Non-Standardized Plant Allergenic Extract [EPC] | 1 | 0.0001 |
| 7 | Carbonic Anhydrase Inhibitor [EPC] | 1 | 0.0000 |
| 8 | Antimetabolite Immunosuppressant [EPC] | 1 | 0.0000 |
| 9 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 1 | 0.0000 |